BioAge Labs, Inc. (NASDAQ:BIOA) Receives $43.50 Average Price Target from Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $43.50.

Several research analysts have recently commented on BIOA shares. Oppenheimer started coverage on BioAge Labs in a report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target on the stock. Citigroup lifted their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Roth Mkm started coverage on BioAge Labs in a report on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Finally, Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th.

BioAge Labs Stock Performance

Shares of BIOA stock opened at $17.02 on Friday. The stock’s fifty day moving average is $17.25 and its two-hundred day moving average is $16.76. The firm has a market capitalization of $756.59 million, a P/E ratio of -7.09 and a beta of 0.94. BioAge Labs has a fifty-two week low of $4.07 and a fifty-two week high of $24.00.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The company had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, equities analysts forecast that BioAge Labs will post -2.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BIOA. Russell Investments Group Ltd. purchased a new position in BioAge Labs in the third quarter worth approximately $27,000. CWM LLC grew its position in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares during the period. Walleye Capital LLC purchased a new stake in BioAge Labs in the 2nd quarter valued at about $64,000. Finally, Bank of America Corp DE raised its holdings in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after buying an additional 3,517 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.